Clinical Trial Update: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating MB-102 for safety and efficacy in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) has been terminated. No further results are r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• MB-102

Snippet

Sponsor: Mustang Bio | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1, Phase 2 | Status: TERMINATED